After trial data for a new medicine proved inconclusive, Sarepta Therapeutics joined with the parents of sick boys to persuade officials it helped.

Topics:  sarepta therapeutics   
  • U.S. FDA panel backs gene therapy for rare form of blindness
    Oct 12 (Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration ... which can range from $300,000 a year to $600,000 a year or more.
    10/12/2017 - 2:55 pm | View Link
  • To appease a patient lobby, did the FDA approve a $300,000 drug that doesn't work?
    A couple of weeks ago, the big insurance company Anthem decided that it wouldn’t pay for Exondys 51, a drug that already had been approved by the Food and ... The drug costs $300,000 a year, and the evidence that it works is almost laughably thin.
    10/28/2016 - 9:06 am | View Link
  • More
  • Phillip Morris Introduces ‘Marlboro M’ Marijuana ...
    MORE NEWS Latest Newsflash3 Side Feature Phillip Morris Introduces ‘Marlboro M’ Marijuana Cigarettes. Phillip Morris, the world’s biggest cigarette producer ...
    11/17/2017 - 8:50 am | View Website
  • SRPT Stock Price
    Sarepta Therapeutics shares dive on safety issues in FDA database. Sarepta Therapeutics Inc. shares declined as much as 8% in morning trade Friday on safety issues ...
    11/15/2017 - 4:59 pm | View Website
  • ECV: News Archiv
    ECV. Der ECV · Editio Cantor Verlag GmbH ist ein mittelständischer Fachverlag mit einem breiten Produktportfolio für die international agierende Pharma-Industrie.
    11/15/2017 - 4:52 pm | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News